Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | IDO1 | P14902 | 5/20 | 0.40 |
| ▸ | TDO2 | P48775 | 4/20 | 0.40 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.38 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.38 |
| ▸ | KCNA5 | P22460 | 7/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1482980 | 0.92 | SMN1; SMN2 (0.39) | SMN1; SMN2IDO1TDO2CYP11B1CYP11B2 | |
| SCHEMBL3059460 | 0.90 | SMN1; SMN2 (0.55) | SMN1; SMN2KCNA5KCNH2 | |
| SCHEMBL11891091 | 0.82 | CYP11B1 (0.39) | SMN1; SMN2IDO1TDO2CYP11B1CYP11B2 | |
| SCHEMBL13089069 | 0.82 | CYP11B1 (0.39) | SMN1; SMN2IDO1TDO2CYP11B1CYP11B2 | |
| SCHEMBL2204312 | 0.79 | ADRA2A (0.47) | IDO1CYP11B2ALDH1A1 | |
| SCHEMBL23704552 | 0.78 | HSP90AA1 (0.40) | SMN1; SMN2CYP11B1CYP11B2TDP1KCNH2 | |
| SCHEMBL1484285 | 0.78 | GAA (0.36) | IDO1TDO2CYP11B1CYP11B2KCNH2 | |
| SCHEMBL13089076 | 0.76 | KCNN4 (0.35) | SMN1; SMN2IDO1TDO2CYP11B1CYP11B2 | |
| SCHEMBL9241069 | 0.75 | ALDH1A1 (0.39) | SMN1; SMN2CYP11B1CYP11B2ALDH1A1TDP1 | |
| SCHEMBL3026300 | 0.75 | TSHR (0.34) | SMN1; SMN2CYP11B1CYP11B2ALDH1A1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120202865-A1 | SUBSTITUTED-ARYL-(IMIDAZOLE)-METHYL)-PHENYL COMPOUNDS AS SUBTYPE SELECTIVE MODULATORS OF ALPHA 2B AND/OR ALPHA 2C ADRENERGIC RECEPTORS | SINHA SANTOSH C (US) | 2012-08-09 | — | — | US | disclosed |
| US-20120202865-A1 | SUBSTITUTED-ARYL-(IMIDAZOLE)-METHYL)-PHENYL COMPOUNDS AS SUBTYPE SELECTIVE MODULATORS OF ALPHA 2B AND/OR ALPHA 2C ADRENERGIC RECEPTORS | SINHA SANTOSH C (US) | 2012-08-09 | — | — | US | disclosed |
| US-8227499-B2 | Substituted-aryl-(imidazole)-methyl)-phenyl compounds as subtype selective modulators of alpha 2B and/or alpha 2C adrenergic receptors | ALLERGAN, INC. (US) | 2012-07-24 | — | — | US | disclosed |
| US-8227499-B2 | Substituted-aryl-(imidazole)-methyl)-phenyl compounds as subtype selective modulators of alpha 2B and/or alpha 2C adrenergic receptors | ALLERGAN, INC. (US) | 2012-07-24 | — | — | US | disclosed |
| US-20110098330-A1 | SUBSTITUTED-ARYL-(IMIDAZOLE)-METHYL)-PHENYL COMPOUNDS AS SUBTYPE SELECTIVE MODULATORS OF ALPHA 2B AND/OR ALPHA 2C ADRENERGIC RECEPTORS | ALLERGAN, INC. | 2011-04-28 | — | — | US | disclosed |
| US-20110098330-A1 | SUBSTITUTED-ARYL-(IMIDAZOLE)-METHYL)-PHENYL COMPOUNDS AS SUBTYPE SELECTIVE MODULATORS OF ALPHA 2B AND/OR ALPHA 2C ADRENERGIC RECEPTORS | ALLERGAN, INC. | 2011-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098330-A1 | SUBSTITUTED-ARYL-(IMIDAZOLE)-METHYL)-PHENYL COMPOUNDS AS SUBTYPE SELECTIVE MODULATORS OF ALPHA 2B AND/OR ALPHA 2C ADRENERGIC RECEPTORS | ADRA2C, ADRB2, ADRB3 | SMN1; SMN2 2648/4885IDO1 1829/4885TDO2 1795/4885 |
| US-20120202865-A1 | SUBSTITUTED-ARYL-(IMIDAZOLE)-METHYL)-PHENYL COMPOUNDS AS SUBTYPE SELECTIVE MODULATORS OF ALPHA 2B AND/OR ALPHA 2C ADRENERGIC RECEPTORS | ADRA2C, ADRB2, ADRB3 | SMN1; SMN2 2742/4885IDO1 1723/4885TDO2 1815/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.